CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
30 hedge funds and large institutions have $5.76M invested in CASI Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
400% more funds holding
Funds holding: 6 → 30 (+24)
84% more capital invested
Capital invested by funds: $3.13M → $5.76M (+$2.64M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.4M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$399K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$243K |
| 4 |
MC
Moors & Cabot
Boston,
Massachusetts
|
+$170K |
| 5 |
WSCM
Wellington Shields Capital Management
New York
|
+$136K |
Top Sellers
CASI Hedge Fund Activity: Q3 2014 in Review
30 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2014, worth a combined $5.76M — up 84% from $3.13M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CASI positions and 0 closed out — a net gain of 24 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.4M.
- 30 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2014, up from 6 in Q2 2014.
- Funds reported $5.76M of CASI Pharmaceuticals stock for Q3 2014, up 84% quarter-over-quarter.
- 24 funds opened new CASI Pharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +24 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2014 was Sabby Management, an estimated $1.4M added.
Based on aggregated 13F filings for Q3 2014.